Aorflex launch at Charing Cross Symposium

TIDMLMT

Lombard Medical Technologies PLC

17 April 2012

Press information

Lombard Medical Technologies PLC

("Lombard Medical" or "Company")

Launch of the new Aorflex(TM) delivery system

at Charing Cross Symposium 2012

London, UK, 17 April 2012 - Lombard Medical Technologies PLC (AIM: LMT), the specialist medical technology company focussed on innovative vascular products, announces the launch of the new Aorflex(TM) delivery system at the 34th International Charing Cross Symposium (14th -17th April).

The new system, Aorflex(TM), combines the clinical excellence of Aorfix(TM) stent graft with the new Aorflex(TM) delivery system which offers a range of clear clinical benefits including:

   --      Greater deployment control with exceptional one to one torque 
   --      Improved visibility during deployment due to new radio opaque marker 
   --      Ease of use with reduced deployment forces 
   --      Improved vascular introduction through the use of hydrophilic coating

CEO of Lombard Medical Technologies, Simon Hubbert, commented:

"The Aorflex system(TM) is part of a series of development projects underway to provide innovative endovascular solutions which meet clinicians' needs and improve patient outcomes. We look forward to launching next generations of our delivery system with further enhancements anticipated as we extend our reach into new and existing markets.

"Lombard Medical has more than 15 years experience in the development of innovative devices for minimally invasive endovascular treatment, this combined with real life clinical use of Aorfix(TM) in over 2,000 patients worldwide provides clinicians with the confidence to treat extreme AAA anatomy without the unknown risks associated with off label use."

- Ends -

About Lombard Medical

Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix(TM), is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix(TM) is currently being commercialised in the EU, and has been submitted to the FDA for approval in the US.

The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.

Further background on the Company can be found at www.lombardmedical.com .

For further information:

 
 Lombard Medical Technologies PLC         Tel: 01235 750 800 
 Simon Hubbert, Chief Executive Officer 
 Ian Ardill, Chief Financial Officer 
 
 Canaccord Genuity Limited                Tel : 020 7523 8000 
 Jamie Adams / Mark Dickenson / Lucy 
  Tilley 
 
 FTI Consulting                           Tel : 020 7831 3113 
 Jonathan Birt / Simon Conway / Susan 
  Quigley

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAUBOKRUAASARR

Lombard Medical Technologies (LSE:LMT)
Historical Stock Chart
From Jul 2024 to Jul 2024